BelizeTuberculosis profile
Population  2017 <1 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) <0.01 (<0.01–0.01) 2.6 (2.4–2.8)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 1.3 (0.91–1.9)
Incidence  (includes HIV+TB) 0.13 (0.12–0.16) 36 (31–41)
Incidence (HIV+TB only) 0.032 (0.021–0.046) 8.6 (5.6–12)
Incidence (MDR/RR-TB)** 0.015 (<0.01–0.045) 4.1 (0.42–12)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females <0.01 (<0.01–<0.01) 0.042 (0.039–0.046) 0.05 (0.045–0.055)
Males <0.01 (<0.01–<0.01) 0.076 (0.068–0.085) 0.085 (0.075–0.095)
Total 0.016 (0.015–0.017) 0.12 (0.1–0.14) 0.13 (0.12–0.16)
TB case notifications, 2017  
Total cases notified 122
Total new and relapse 117
          - % tested with rapid diagnostics at time of diagnosis 44%
          - % with known HIV status 100%
          - % pulmonary 97%
          - % bacteriologically confirmed among pulmonary 62%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.11 (0.09–0.13)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 28 24%
          - on antiretroviral therapy 27 96%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  18
(12–24)
Estimated % of TB cases with MDR/RR-TB 2.3% (0.79–4.5) 100% (29–100)  
% notified tested for rifampicin resistance 39% 50% 49
MDR/RR-TB cases tested for resistance to second-line drugs   1
Laboratory-confirmed cases MDR/RR-TB: 1, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 0, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 62% 120
Previously treated cases, excluding relapse, registered in 2016   0
HIV-positive TB cases registered in 2016 36% 36
MDR/RR-TB cases started on second-line treatment in 2015 100% 1
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
13% (9.5–20)
TB financing, 2018  
National TB budget (US$ millions) <1
Funding source: 7% domestic, 93% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-11-20 Data: www.who.int/tb/data